IL-15 Stimulation with TIGIT Blockade Reverses CD155-Mediated NK Cell
Author Manuscript Published OnlineFirst on June 26, 2020; DOI: 10.1158/1078-0432.CCR-20-0575 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. IL-15 stimulation with TIGIT blockade reverses CD155-mediated NK cell dysfunction in melanoma Joe-Marc Chauvin1, Mignane Ka1, Ornella Pagliano1, Carmine Menna1, Quanquan Ding1, Richelle DeBlasio1, Cindy Sanders1, Jiajie Hou2, Xian-Yang Li3, Soldano Ferrone4, Diwakar Davar1, John M. Kirkwood1, Robert Johnston5, Alan J. Korman5, Mark J. Smyth3, and Hassane M. Zarour1,6. 1Department of Medicine and Division of Hematology/Oncology, University of Pittsburgh, School of Medicine, Pittsburgh, PA 15213, USA. 2Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China. 3Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Queensland, Australia. 4Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. 5Biologics Discovery California, Bristol-Myers Squibb, Redwood City, CA 94063, USA. 6Department of Immunology, University of Pittsburgh, School of Medicine, Pittsburgh, PA 15213, USA. Running title: IL-15 and TIGIT blockade reverse NK dysfunction in melanoma Keywords: Melanoma, Immunotherapy, TIGIT, IL-15, NK cells This work was supported by NIH/NCI grants R01CA228181 and R01CA222203 (to HMZ), a research grant by Bristol-Myers Squibb BMS (to HMZ), a cancer vaccine collaborative clinical strategy team grant (to HMZ), and NCI grant P50CA121973 (to 1 Downloaded from clincancerres.aacrjournals.org on September 25, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on June 26, 2020; DOI: 10.1158/1078-0432.CCR-20-0575 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
[Show full text]